Drug Profile
Lintitript
Alternative Names: SR 27897Latest Information Update: 16 Mar 2009
Price :
$50
*
At a glance
- Originator sanofi-aventis
- Class Antiulcers; Indoleacetic acids; Small molecules; Thiazoles
- Mechanism of Action Cholecystokinin A receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Anorexia nervosa; Gastrointestinal disorders; Pancreatic cancer; Psychotic disorders
Most Recent Events
- 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form Sanofi-Aventis
- 03 Oct 2002 Discontinued - Phase-II for Pancreatic cancer in France (PO)
- 27 Aug 1999 Sanofi has merged with Synthélabo to form Sanofi-Synthélabo